Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.

ABSTRACT:

Objective

To examine the use of the Prostate Health Index (PHI) as a continuous variable in multivariable risk assessment for aggressive prostate cancer in a large multicentre US study.

Materials and methods

The study population included 728 men, with prostate-specific antigen (PSA) levels of 2-10 ng/mL and a negative digital rectal examination, enrolled in a prospective, multi-site early detection trial. The primary endpoint was aggressive prostate cancer, defined as biopsy Gleason score ≥7. First, we evaluated whether the addition of PHI improves the performance of currently available risk calculators (the Prostate Cancer Prevention Trial [PCPT] and European Randomised Study of Screening for Prostate Cancer [ERSPC] risk calculators). We also designed and internally validat

SUBMITTER: Loeb S 

PROVIDER: S-EPMC5392379 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature